Utilization and Adherence Patterns of Subcutaneously Administered Anti–Tumor Necrosis Factor Treatment Among Rheumatoid Arthritis Patients
Open Access
- 1 May 2014
- journal article
- Published by Elsevier BV in Clinical Therapeutics
- Vol. 36 (5), 737-747
- https://doi.org/10.1016/j.clinthera.2014.02.019
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: An achievable target?Autoimmunity Reviews, 2013
- Applying science in practice: the optimization of biological therapy in rheumatoid arthritisArthritis Research & Therapy, 2010
- Adherence to biologic DMARD therapies in rheumatoid arthritisExpert Opinion on Biological Therapy, 2010
- Adherence to Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid ArthritisOrthopaedic Nursing, 2010
- Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosusInternational Journal of Clinical Rheumatology, 2010
- Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disabilityArthritis Research & Therapy, 2009
- Golimumab, a human antibody to tumour necrosis factor given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD StudyAnnals Of The Rheumatic Diseases, 2008
- Medication Compliance and Persistence: Terminology and DefinitionsValue in Health, 2008
- Challenges of Using Medical Insurance Claims Data for Utilization AnalysisAmerican Journal of Medical Quality, 2006
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987